

May 2023 Shareholder Update

Dear Neopharma Technologies Shareholders,

I am very pleased to provide the following company updates for Neopharma Technologies Ltd:

- 1) We have just received CE certification (for European Market Access) for our NEOTEST DOA product range I have attached our product brochure. Our products are all empowered with NEOVAULT giving a full chain-of-custody of Drug Testing Results. This is a significant milestone for our company as it enables us to solidify partnerships with distributors throughout the EU and gives us access to 27 countries. Europe is the second largest global market for drug testing representing almost 25% of the market, with the US representing 50% of the growing \$6.5 billion Drug Testing Industry.



- 2) The CE certification also enables us to sell into the US under "Insurance and Employment Use Only" and "Forensic Use Only." As a result of this, Neopharma Technologies is traveling to the US with our partners Global Risk Group to Bellevue, WA, for the largest Drug Testing Conference in the US with National Drug & Alcohol Screening Organisation. Neopharma Technologies is a corporate sponsor of the event alongside the following companies:





- 3) This is Neopharma Technologies' official soft launch into the US market launch with 5 of our products, including TamperLoks, under "Insurance and Employment Use Only" and "Forensic Use Only." Marcus and I will be traveling to the US to meet with strategically important groups in the US Drugs testing market and key potential sub-distributors. We have also arranged meetings with CEOs and senior management of our product manufacturers Healgen in Houston, for our NEOTEST DOA range, and with WHPM in Irwindale for TamperLoks for the US market. US FDA approval of TamperLoks is expected in July/August and US FDA approval for NEOTEST DOA range is expected in June/July. This will open up our

company's retail and Federal Government channels. Building a pipeline of sales from these channels will be a catalyst milestone for Neopharma's ASX listing this year.



WHPM Headquarters Irwindale.

- 4) Neopharma Technologies is committed to upholding the highest global security and privacy standards for its innovative IT Platform NEOVAULT. To this end we are working to ensure our organization's IT systems and infrastructure is certified to the highest international standards of ISO27001, SOC2, GDPR, and HIPAA. We have been working towards these certifications for some time now and have just concluded our internal audit on the company's IT systems. For the final step in this process, a third-party external auditor is now engaged, with the ISO27001 certification anticipated before our US launch at the end of May. Achieving these international standards is a significant milestone for our company, and it positions us as a major innovator in the IT side of the Drug Testing Industry. This distinction will give us a strong competitive edge, particularly when pursuing US federal government contracts.
- 5) The other market that is part of our global growth strategy is our home market of Australia. On this front we have appointed a distributor with a volume of 100,000 units per month. We have achieved Preliminary Lab Verification for our NEOTEST Oral Fluid Test and will shortly be commencing the Full Verification expected within 4 weeks now we have achieved CE. We are evaluating both WHPM's Split Cup and Healgen's split and expect the results within the next 4 weeks. On the success of this, we will be able to start Lab Verification studies for TamperLoks for Australian Market access. The previous AUS lab verification tests for TamperLoks found the sensitivity of one of the 6 test strips did not meet Australian Standards. Australia has the highest standards compared to anywhere in the world for Drug Testing, with strict drug cut-offs and sensitivities. We are working with WHPM our drug test strip supplier, to manufacture this particular test strip to meet the more sensitive parameters of the Australian Standards. Within the next two months, there are significant company milestones we expect to achieve, and we are getting ready to capitalize on these new market entries. As discussed in previous webinars our company's business strategy has been structured to scale up as required by working to build relationships with high volume

manufactures, so that on successful approvals and certifications we are well equipped to hit the ground running across global markets with distribution relationships already in place and talks with others progressing.

- 6) We are also excited to share our progress on developing NEO-vision, a cutting-edge addition to our suite of solutions within the NEOVAULT IT platform. NEO-vision is an AI and AR-driven vision system designed to analyze images and videos in real-time, specifically identifying our proprietary testing cups, categorizing test outcomes, and pinpointing any abnormalities within the testing apparatus. Our primary goal in developing NEO-vision is to significantly minimize the possibility of human error while simultaneously accelerating the decision-making process and maintaining the highest test credibility. By leveraging advanced AI and AR technology, NEO-vision will be able to detect any potential tampering or breaches in the testing cup that might otherwise go unnoticed by the human eye. Currently in the Beta stage paired with Tamperlocks. As we continue to innovate, we are confident that NEO-vision will be a valuable asset in reinforcing the integrity and reliability of our testing solutions.

The catalyst events for a successful IPO are for Neopharma Technologies to achieve US FDA approval for our range of products, including NEOTEST Single Chamber, NEOTEST Dip Card, and TamperLoks, the launch of our AI Vision technology with NEOVAULT and achieving ISO, HIPPA, SOC 2 and GDPR certifications and commercial orders of 500,000 units across our range of products. The company is on track to achieve these milestones by August.

If you have any further questions please don't hesitate to contact marcus@neopharmatechnologies.com or myself shaun@neopharmatechnologies.com .